Naptumomab estafenatox

Naptumomab estafenatox

Schematic image of naptumomab estafenatox. VH, VL: variable (antigen binding) domains of antibody fragment CH1, CL: constant domains of antibody fragment SAg: superantigen SEA/E-120
Monoclonal antibody
Type	Fab fragment
Source	Mouse
Target	5T4
Clinical data
ATC code	none
Identifiers
CAS Number	676258-98-3  N
ChemSpider	none
UNII	93T929W6LC
Chemical and physical data
Formula	C3255H5025N855O1050S18
Molar mass	73513.02 g·mol−1
NY  (what is this?)    (verify)

Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma ^[1] and renal cell carcinoma. ^[2]

Mechanism of action

Chemically, it is a fusion protein consisting of the antigen-binding fragment (Fab) of a monoclonal antibody with the superantigen staphylococcal enterotoxin A (SEA/E-120, "estafenatox"). ^[3] The Fab binds to 5T4, an antigen expressed by various tumor cells, and the superantigen induces an immune response by activating T lymphocytes. ^[4]

See also

• Nacolomab tafenatox, a drug with a similar chemical structure and mechanism

References

1. Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, et al. (September 2009). "Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer". Journal of Clinical Oncology. 27 (25): 4116–23. doi:10.1200/JCO.2008.20.2515. PMC   2734423 . PMID   19636016.
2. Clinical trial number NCT00420888 for "ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma" at ClinicalTrials.gov
3. "Naptumomabum estafenatoxum" (PDF). WHO Drug Information. 20 (4): 291. 2006. Archived from the original (PDF) on 2011-02-01.
4. Eisen T, Hedlund G, Forsberg G, Hawkins R (February 2014). "Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin". Current Oncology Reports. 16 (2): 370. doi:10.1007/s11912-013-0370-0. PMC   3918406 . PMID   24445502.